Rheumatoid arthritis (RA) affects around 400,000 people in the UK, according to the National Rheumatoid Arthritis Society (NRAS). It is one of the most common autoimmune conditions community pharmacists encounter, and the medicines used to manage it — particularly methotrexate — require careful counselling that pharmacists are uniquely placed to deliver.

This guide covers the drug classes used in RA, the counselling points that prevent harm, and the red flags that should prompt urgent referral.

The treatment landscape

RA treatment follows a step-up approach, starting with conventional disease-modifying anti-rheumatic drugs (cDMARDs) and escalating to biologics and targeted synthetic DMARDs if needed.

NICE guideline CG79 emphasises early aggressive treatment. The goal is remission or low disease activity within six months.

Methotrexate: the counselling that prevents harm

Methotrexate is the cornerstone of RA treatment and one of the highest-risk medicines dispensed in community pharmacy. The NPSA issued a patient safety alert in 2020 specifically about methotrexate dosing errors. Key counselling points:

Once-weekly dosing. Methotrexate for RA is taken once a week, not daily. This is the single most dangerous error — daily dosing has caused deaths. At every dispensing, pharmacists should confirm the patient knows which day they take it and that it is one day per week only. The prescription should specify the day.

Folic acid supplementation. Patients on methotrexate should take folic acid 5mg once weekly (or up to 6 days per week, excluding the methotrexate day) to reduce side effects including mouth ulcers, nausea, and hepatotoxicity. If a patient on methotrexate is not also prescribed folic acid, query this with the prescriber.

Blood monitoring. Methotrexate requires regular blood tests — full blood count, liver function, and renal function. Initially these are fortnightly, moving to monthly and then every two to three months once stable. If a patient mentions they have missed blood tests, advise them to arrange these before the next dose.

Infection risk. Methotrexate suppresses the immune system. Patients should be counselled to report signs of infection promptly — fever, sore throat, unexplained bruising, or mouth ulcers that do not resolve. Live vaccines are contraindicated.

Pregnancy. Methotrexate is teratogenic and must be stopped at least three months before conception in women and men. Effective contraception is required throughout treatment.

Alcohol. The BNF advises patients to avoid excessive alcohol due to the additive hepatotoxicity risk. "Excessive" is not precisely defined, but most rheumatology units advise staying within the Chief Medical Officer's 14 units per week guidance and having several alcohol-free days.

Other conventional DMARDs

Sulfasalazine requires monitoring for blood dyscrasias (FBC at baseline and monthly for the first three months). It can discolour urine and contact lenses orange. Patients should be counselled about this cosmetic effect.

Leflunomide has a very long half-life due to enterohepatic recycling. If it needs to be stopped urgently (e.g. for pregnancy planning), a washout procedure with colestyramine is required. Pharmacists should be aware of this if a patient mentions wanting to conceive.

Hydroxychloroquine carries a risk of retinal toxicity with long-term use. Annual eye screening is recommended after five years of use (or sooner with risk factors). Pharmacists can ask whether the patient is having regular eye checks.

Biologic DMARDs and injection technique

Many RA patients self-inject biologics at home — adalimumab, etanercept, certolizumab, and others are supplied as pre-filled pens or syringes. Community pharmacists may be asked about:

• Storage: biologics must be kept refrigerated (2-8°C). Patients should allow the injection to reach room temperature before administering (usually 15-30 minutes out of the fridge). Do not shake.
• Injection site: rotate between thighs and abdomen. Avoid areas that are tender, bruised, or scarred.
• Missed doses: each biologic has different guidance on what to do if a dose is missed. Refer to the individual product literature or the prescribing team.
• Infection: as with methotrexate, biologics increase infection risk. Patients should withhold their injection and contact their rheumatology team if they have an active infection.

JAK inhibitors: newer oral options

Janus kinase (JAK) inhibitors are oral alternatives to injectable biologics. They are effective but carry specific safety signals:

• Cardiovascular risk: the ORAL Surveillance trial found increased cardiovascular events with tofacitinib compared to TNF inhibitors in patients over 50 with cardiovascular risk factors. MHRA has issued safety advice. JAK inhibitors should be used with caution in patients with cardiovascular risk factors.
• Venous thromboembolism: increased risk of DVT and PE has been reported.
• Malignancy: a small increased risk of certain cancers has been observed.

Pharmacists should be aware of these signals and ensure patients on JAK inhibitors are having appropriate monitoring.

OTC considerations

Patients with RA frequently ask about OTC options for pain management:

• Paracetamol remains appropriate as an adjunct, though evidence of benefit in RA specifically is limited.
• Oral NSAIDs (ibuprofen, naproxen) should be used cautiously — many RA patients are on methotrexate (NSAIDs reduce methotrexate clearance) or have cardiovascular risk factors. Check before recommending.
• Topical NSAIDs may be suitable for localised symptoms without the systemic interaction risk.
• Glucosamine and chondroitin — NICE does not recommend these for any form of arthritis. Pharmacists should communicate this clearly if asked.
• Turmeric/curcumin supplements — no robust evidence of benefit; potential interaction with anticoagulants.

When to refer

• Hot, swollen joint in a patient not yet diagnosed — possible new-onset inflammatory arthritis requiring urgent rheumatology assessment
• Signs of infection in an immunosuppressed patient — fever, rigidity, confusion
• New or worsening breathlessness — methotrexate can cause pneumonitis (rare but serious)
• Pregnancy planning — specialist advice needed for DMARD washout timing
• Persistent mouth ulcers or unexplained bruising — possible methotrexate toxicity

The pharmacy role

Community pharmacists are often the healthcare professional RA patients see most regularly. The New Medicine Service supports patients starting methotrexate or other DMARDs. Structured Medication Reviews can identify NSAID interactions, missed folic acid prescriptions, or patients overdue for blood monitoring.

PharmSee tracks 1,715 active pharmacy vacancies across England, including community and hospital roles where rheumatology and immunology medicines management features prominently. For pharmacists considering specialist rheumatology practice, NHS Jobs listings occasionally include dedicated rheumatology pharmacist positions.

Sources

• NICE guideline CG79: Rheumatoid arthritis in adults — management (2009, updated 2018)
• National Rheumatoid Arthritis Society (NRAS): prevalence data
• BNF: methotrexate, sulfasalazine, leflunomide, hydroxychloroquine monographs
• NPSA: Patient safety alert — methotrexate (2020)
• MHRA: JAK inhibitor safety advice
• PharmSee vacancy tracker: 1,715 active roles as of 15 April 2026